BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Releases Positive Data from TGR-63 Preclinical Studies

IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, is reporting on preclinical results in an Alzheimer’s mouse model. According to the announcement, the model demonstrates the potential of IGC Pharma’s therapeutic candidate, TGR-63, to combat Alzheimer’s disease. Specifically, the students show a “significant reduction” in amyloid plaque, totaling 78% in the cortex and 85% in the hippocampus. These findings suggest that TGR-63 has potential to slow or even reverse the progression of Alzheimer’s. These positive results could mean that TGR-63 will advance through clinical trials. The company noted that it anticipates beginning a phase 1 trial for the candidate next year, although there is no guarantee. “These preclinical results for TGR-63 are highly encouraging,” said IGC Pharma CEO Ram Mukunda in the press release. “The significant reduction in amyloid plaque burden in an Alzheimer’s mouse model observed in this study suggests TGR-63 has the potential to be a transformative treatment for Alzheimer’s disease. TGR-63 is filed for patent protection in U.S. patent application, further strengthening its potential value. We are committed to advancing TGR-63 through clinical trials to determine its efficacy and safety in human patients, offering new hope for the 50 million individuals affected by this devastating illness.”

To view the full press release, visit https://ibn.fm/0hYER

About IGC Pharma

IGC Pharma is focused on Alzheimer’s disease, developing innovative solutions to address this devastating illness. The company’s mission is to transform the landscape of Alzheimer’s treatment with a robust pipeline of five promising drug candidates. IGC-AD1 is currently undergoing a phase 2 clinical trial for agitation in dementia associated with Alzheimer’s. The remaining four molecules are in the preclinical stage of development. TGR-63 disrupts the progression of Alzheimer’s by targeting Aβ plaques, a key hallmark of Alzheimer’s. IGC-M3 aims to inhibit the aggregation of Aβ plaques, potentially impacting early-stage Alzheimer’s. IGC-1C targets tau protein and neurofibrillary tangles, representing a forward-thinking approach to Alzheimer’s therapy. LMP is designed to target multiple hallmarks of Alzheimer’s including plaques and tangles for a comprehensive approach to the disease. In addition to its drug-development pipeline, IGC Pharma seeks to leverage artificial intelligence (“AI”) for Alzheimer’s research. The company’s AI projects encompass various areas, including clinical trial optimization and early detection of Alzheimer’s. For more information, visit the company’s website at www.IGCInc.us.

NOTE TO INVESTORS: The latest news and updates relating to IGC are available in the company’s newsroom at https://ibn.fm/IGC

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.